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Since 2000–2001, dengue virus type 1 has circulated 
in the Pacifi c region. However, in 2007, type 4 reemerged 
and has almost completely displaced the strains of type 1. 
If only 1 serotype circulates at any time and is replaced ap-
proximately every 5 years, DENV-3 may reappear in 2012.
During the past 10–15 years in the Pacifi c island na-tion states, sustained transmission of only 1 serotype 
of dengue virus (DENV) has occurred at any given time 
(1). This single serotype is in marked contrast to all 4 se-
rotypes that cocirculate in many countries in Southeast 
Asia where dengue is endemic. During 1997–2000 in the 
Pacifi c region, the serotype recovered from patients was 
almost exclusively DENV-2, but during 2000–2001, <1 
year, DENV-2 was displaced by multiple genotypes of 
DENV-1 (2). We describe rapid replacement of DENV-1 
by DENV-4 during 2008.
The Study
In May 2008, an outbreak of a dengue-like illness be-
gan on the island of Tarawa in Kiribati (Figure 1). Immu-
nochromatographic and ELISA assays (PanBio, Brisbane, 
Queensland, Australia) detected anti–dengue virus immu-
noglobulin (Ig) M or high titers (>1,280) of anti–dengue 
virus IgG in serum from 5 of 18 patients. DENV-4 trans-
mission had not been reported in the Pacifi c region for >1 
decade; however, after serum was cultured with Aedes 
albopictus C6/36 cells, DENV-4 was recovered from 5 of 
the 13 serum samples from patients who had no detectable 
anti-DENV IgG or IgM (2).
In July 2008, a similar outbreak began in Samoa. Se-
rum from 87 of 469 patients with suspected dengue con-
tained anti-DENV IgM or high titers of anti-DENV IgG 
(ELISA; PanBio). Serum from 7 of the 87 patients with 
anti-DENV IgM contained no detectable anti-DENV IgG, 
suggesting a primary infection. DENV-4 was recovered 
from 42 of the 382 seronegative patients when serum was 
cultured with C6/36 cells.
From June 2007 through February 2008 in Tonga, 
small numbers of dengue cases, confi rmed by ELISA, had 
been reported; the only DENV isolates recovered from 
these patients were 4 isolates of DENV-1 (J. Aaskov, un-
pub. data). However, in December 2008 and January 2009, 
only 4 DENV-4 isolates were recovered from 55 serum 
samples collected from patients with suspected dengue in 
Tonga.
In November 2008 in New Caledonia, DENV-4 trans-
mission was detected after the virus had been introduced by 
residents returning from Vanuatu; and in February 2009, 
DENV-4 transmission was detected in French Polynesia 
after it had been introduced there by travelers from New 
Caledonia. In June 2009, DENV-1 and DENV-4 were co-
circulating in New Caledonia and French Polynesia.
DENV-4 was reportedly recovered from a traveler re-
turning to Taiwan from the Solomon Islands in 2007 (3) 
and from a resident of the Solomon Islands in April 2008 
(Alyssa Pyke, pers. comm.). DENV-1 had been circulating 
in the Solomon Islands until at least 2002, preceding the 
2003 arrival of a multinational peacekeeping force com-
posed of persons from Australia, Papua New Guinea, New 
Zealand, Fiji, and Tonga. The chronology of these and 
other reports of dengue outbreaks involving DENV-4 are 
shown in the Table.
During some of these outbreaks, the envelope (E) pro-
tein genes of DENV-4 recovered from patients were am-
plifi ed by reverse transcription–PCR (2) by using forward 
primer 5′-GGATTCGCTCTCTTGGCAGGATTTATG-3′ 
and reverse primer 5′- GCTTCCACACTTCAATTCTTTC-
CCACTCCA-3′, corresponding to regions in the premem-
brane and nonstructural protein gene 1, respectively, and 
the consensus nucleotide sequences of the resultant cDNA 
determined by Dye Terminator Cycle Sequencing on an 
automated sequencer (ABI Prism, Australian Genome 
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Research Facility, Brisbane, Queensland, Australia). Se-
quencing was performed by using the primers above as 
well as 5′-AACACAGCATGGGACAACAGT-3′ and 5′-
GACTCAAACATCTTACCAATGGAG-3′. Sequences 
were analyzed by using ClustalW, Seqboot, DNADist, 
Kitsch, and Consense software (www.angis.org.au) from 
the Australian National Genome Information Service of 
the University of Sydney. Phylogenetic analyses (Human 
Research Ethics Approval QUT-0700000910) of the nucle-
otide sequences of the E genes of DENV-4 that we recov-
ered from patients in Kiribati, Samoa, and Tonga and those 
of strains of DENV-4 recovered by others showed that all 
isolates from this recent outbreak in the Pacifi c were closely 
related but distinct from other DENV-4 isolates for which 
sequences were available (Figure 2), including isolates re-
covered in the Pacifi c region during the 1970s and 1980s.
The chronology of the recovery of DENV-4 from pa-
tients in the region and the phylogenetic analyses suggest 
that DENV-4 was introduced from Indonesia/Malaysia 
into the Pacifi c region, possibly into the Solomon Islands, 
sometime before 2007. The 3 genotypes of DENV-1 re-
sponsible for the earlier outbreak also originated in South-
east Asia (Philippines, Malaysia, Myanmar/Thailand) (2). 
The relative genetic homogeneity of the DENV-4 recov-
ered during this most recent outbreak in the Pacifi c region 
(24 variable nucleotide sites in the E genes of 20 isolates 
resulting in 9 variable amino acid sites) suggests introduc-
tion of a single genotype rather than introduction of mul-
tiple genotypes and to different locations, as was the case 
with DENV-1 (2). The E proteins of all recent DENV-4 
isolates from the Pacifi c region had isoleucine at position 
E365 rather than the threonine that was found at this posi-
tion in earlier DENV-4 isolates. All Pacifi c region isolates 
except DENV4 Kiribati08.278 also had isoleucine at E335 
rather than valine, which was found at this position in most 
earlier isolates. These 2 aa changes occurred in a region of 
domain III of the E protein of fl aviviruses rich in epitopes 
recognized by serum from dengue patients and by neutral-
izing monoclonal antibodies (4–6); they occurred adjacent 
to the change at E390 in DENV-2, which was associated 
with the appearance of dengue hemorrhagic fever in South 
America (7).
Conclusions
Outbreaks of dengue in the Pacifi c region are initiated 
by the introduction of DENV, usually from Southeast Asia, 
but the populations of most Pacifi c island nation states are 
too small to sustain transmission of a single DENV sero-
type for >4–5 years. The interisland mobility of the human 
population in this region ensures rapid spread of any newly 
introduced viruses.
That the spread of dengue virus serotypes through the 
Pacifi c should be so synchronized is remarkable. This syn-
chronization may refl ect the relatively small populations of 
most island states (≈250,000 residents), high attack rates, 
and a high birth rate (≈30% of the population is <14 years 
of age). If only 1 DENV serotype circulates at any time, 
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Table. Chronology of appearance of dengue virus type 4, Pacific 
region
Date of 
appearance Country Source/reference 
2007 Solomon Islands (3)
2008 Apr Nauru T. Bryar, pers. comm.* 
2008 May Kiribati This study 
2008 Jul Samoa This study 
2008 Jul American Samoa T. Bryar, pers. comm.* 
2008 Jul Palau T. Bryar, pers. comm.* 
2008 Aug Cook Islands T. Bryar, pers. comm.* 
2008 Aug Fiji T. Bryar, pers. comm.* 
2008 Aug Niue T. Bryar, pers. comm.* 
2008 Oct Vanuatu T. Bryar, pers. comm.* 
2008 Dec Tonga This study 
2008 Nov New Caledonia This study 
2009 Feb French Polynesia T. Bryar, pers. comm.* 
2009 Jun Chile (Easter Island) ProMED-mail†
*Western Pacific Regional Office, World Health Organization.  
†www.promedmail.org/pls/otn/f?p=2400:1202:1356950393966944::NO::F2
400_P1202_CHECK_DISPLAY,F2400_P1202_PUB_MAIL_ID:X,78506 
0.01 
Myanmar05.62705 
Vietnam03.906 
Cambodia01.K072 
Malaysia04.23476 
Malaysia01.22713 
Indonesia07.0712
Indonesia04.SW38i 
Tonga08.14 
Kiribati08.278 
Kiribati08.277 
SolomonIs07.12aTW
Samoa08.473 
Kiribati08.269 
Kitibati08.265 
Kiribati08.266 
Tonga08.4
Fiji08.3953 
Samoa08.293
Samoa08.203
Samoa08.97 
SolomonIs08
Samoa08.78 
Samoa08.421 
Vanuatu09.4214 
New Caledonia08.5073
New Caledonia08.4257
New Caledonia09.39 
Vanuatu08.4215 
Thailand00.0734 
Singapore01.4553 
Singapore01.4603 
Tahiti85.114 
Tahiti79.S44754 
New Caledonia84 
New Caledonia81.5489 
100
100
100 
100
100
99
90
88
73
Figure 2. Phylogenetic relationships between the envelope (E) 
protein genes of dengue type 4 viruses recovered from patients 
from Pacifi c island nation states during 2007–2009 outbreaks 
and from dengue type 4 viruses from Southeast Asia and earlier 
outbreaks in the Pacifi c region. Bootstrap values are shown for key 
nodes. Scale bar represents 0.01 nt changes per site.
Displacement of Dengue Virus Type 1 by Type 4
and serotype replacement occurs approximately every 5 
years, these data suggest that ≈30% (75,000) of 250,000 
susceptible hosts are suffi cient in these settings to support 
a serotype replacement and that DENV-3 may reappear in 
the Pacifi c island states in ≈2012.
At this stage of study, data are insuffi cient for draw-
ing conclusions about a role for the amino acid changes 
at E335 and E365 in the reemergence of DENV-4 in the 
Pacifi c region. There may be value in delineating the fac-
tors that appear to enable multiple DENV serotypes to 
circulate in urban areas of more developed Pacifi c nations 
(e.g., French Polynesia, New Caledonia, Australia) but that 
appear to prevent cocirculation of DENV serotypes in na-
tions that are less developed but rapidly becoming urban-
ized. Such a study, however, would require more robust 
and comprehensive dengue surveillance programs than ex-
ist in many of these nations.
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